The OPTIMA-5 trial is a prospective, multi-center, randomized, patient blinded, controlled
trial comparing a single bolus of half-dose recombinant staphylokinase (r-SAK) with normal
saline (NS) in patients with ST-segment elevation myocardial infarction (STEMI) presenting
≤12 hours of symptom onset and expected to undergo primary percutaneous coronary intervention
(PPCI) within 120 minutes. The results of OPTIMA-5 showed that a single bolus r-SAK prior to
PPCI for STEMI improves infarct related artery (IRA) patency and reduces infarct size without
increasing major bleeding. On this basis, this study was designed to investigate the effect
of the novel reperfusion strategy on 1-year outcomes of patients with STEMI.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University